2025 Guidance: Q4 2025 revenue expected to exceed $4.5 million, representing ~100% year-over-year growth versus Q4 2024. Full-year 2025 pro forma revenue expected to exceed $20 million, representing ...
ESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback